对接受PCI的急性冠脉综合征患者实施基因多态性个体化抗血小板聚集治疗的效果  

Effects of individualized antiplatelet aggregation therapy with genetic polymorphisms in patients with acute coronary syndromes undergoing PCI

作　　者：智勇刚[1] 江丽 潘蕾羽[3] ZHI Yonggang;JIANG Li;PAN Leiyu(Department of Pharmacy,the First Affiliated Hospital of Shihezi Univ ersity Medical College,Shihezi xinjiang 832008;Shihezi S econd Community Health Service Center,Shihezi xinjiang 832008;The First Affiliated Hospital of Medical College of Shihezi University,Shihezi xinjiang 832008)

机构地区：[1]石河子大学医学院第一附属医院药剂科,新疆石河子832008 [2]石河子第二社区卫生服务中心,新疆石河子832008 [3]石河子大学医学院第一附属医院,新疆石河子832008

出　　处：《当代医药论丛》2021年第9期93-94,共2页

摘　　要：目的:探讨对进行经皮冠状动脉介入治疗(PCI)的急性冠脉综合征(ACS)患者实施基因多态性个体化抗血小板聚集治疗的效果。方法:选取2019年1月至2019年12月期间在石河子大学医学院第一附属医院进行PCI的78例ACS患者作为研究的对象。将这78例患者分为观察组和对照组。对对照组患者进行常规的抗血小板聚集治疗,对观察组患者进行基因多态性个体化抗血小板聚集治疗。治疗结束后,比较两组患者不良心血管事件的发生率和出血性疾病的发生率。结果:观察组患者不良心血管事件的发生率低于对照组患者,P<0.05。两组患者出血性并发症的发生率大体相当,P>0.05。结论:对进行PCI的ACS患者实施基因多态性个体化抗血小板聚集治疗可有效地降低其不良心血管事件的发生率,且不会增加其患出血性并发症的发生率。Objective:To investigate the effect of individualized anti-platelet aggregation therapy with gene polymorphism in patients with acute coronary syndrome(ACS)undergoing percutaneous coronary intervention(PCI).METHODS:78 patients with ACS who underwent PCI in the First Affiliated Hospital of Shihezi University School of Medicine from January 2019 to December 2019 were selected as the subjects.The 78 patients were divided into observation group and control group.Patients in the control group were treated with conventional antiplatelet aggregation therapy,and patients in the observation group were treated with individualized antiplatelet aggregation therapy based on gene polymorphism.After the treatment,the incidence of adverse cardiovascular events and hemorrhagic diseases were compared between the two groups.Results:The incidence of adverse cardiovascular events in observation group was lower than that in control group(P<0.05).The incidence of hemorrhagic complications in 2 groups was similar(P>0.05).Conclusion:Individualized antiplatelet aggregation therapy with gene polymorphism in ACS patients undergoing PCI can effectively reduce the incidence of adverse cardiovascular events and does not increase the incidence of hemorrhagic compl ications.

关 键 词：经皮冠状动脉介入治疗 急性冠脉综合征 基因多态性 抗血小板聚集治疗 

分 类 号：R543.3[医药卫生—心血管疾病]